8-K: Artiva Biotherapeutics CEO, COO Exchange Underwater Options for RSUs

Artiva Biotherapeutics implemented an option for RSU exchange program to enhance employee retention and align interests with stockholders.

Summary

• Artiva Biotherapeutics, Inc. entered into Option for RSU Exchange Agreements on December 10-11, 2025, with a limited number of employees, including the President and CEO, Fred Aslan, and the Chief Operating Officer, Jennifer Bush.
• The program offers a one-time opportunity for eligible participants to surrender outstanding stock options with exercise prices greater than the current fair market value of the company's common stock in exchange for restricted stock units (RSUs).
• The company's Board of Directors approved the exchange program, including the exchange ratio and vesting terms applicable to the RSUs.
• The RSU grants became effective on December 12, 2025.
• Dr. Aslan surrendered options to purchase 869,136 shares of common stock (566,470 vested and 302,666 unvested).
• Ms. Bush surrendered options to purchase 84,877 shares of common stock (60,372 vested and 24,506 unvested).
• In exchange for their vested options, Dr. Aslan received 566,470 RSUs and Ms. Bush received 60,371 RSUs, with vesting scheduled for 50% on August 15, 2026, and 25% on each of November 15, 2026, and February 15, 2027. Full acceleration of vesting occurs upon termination without Cause or resignation for Good Reason.
• In exchange for their unvested options, Dr. Aslan received 302,666 RSUs and Ms. Bush received 24,506 RSUs, which will vest between August 15, 2026, and February 15, 2029. An additional six months of vesting will be accelerated upon termination without Cause or resignation for Good Reason.
• The Option for RSU Exchange Agreements confirm the exchange is irrevocable upon execution.

Sentiment

Score: 6

Explanation: While the program addresses a negative (underwater options) and aims to improve retention, it also highlights past stock underperformance. The proactive measure to realign incentives is positive for long-term stability, but the underlying reason for the exchange is not.

Positives

• The program aims to enhance retention of key employees, including the President and CEO, and the Chief Operating Officer.
• It aligns employee interests with those of the company's stockholders by replacing underwater options with equity awards that have current value and additional vesting requirements.
• The Board of Directors approved the exchange program, indicating formal governance oversight and strategic intent.

Negatives

• The existence of 'underwater' options indicates a previous decline in the company's stock price, which necessitated this exchange.
• The program benefits a 'limited number of employees,' which could potentially create internal disparities.
• The RSU grants, while replacing existing options, represent a future dilution event for existing shareholders as they convert to common stock.

Risks

• Risk of employee dissatisfaction if the program is not perceived as fair or if the company's stock price continues to underperform.
• Potential for future stock price volatility to impact the value of the new RSUs, affecting their incentive and retention effectiveness.
• Dilution risk for existing shareholders from the RSU grants when they vest and convert to common stock.

Future Outlook

The vesting schedules for the new Restricted Stock Units (RSUs) extend to February 15, 2029, indicating an expectation of continued employment and performance alignment from key executives and employees over this period. The program is designed to enhance long-term retention and motivation.

Management Comments

• The purpose of the exchange program is to enhance retention and align the interests of employees with those of the Company’s stockholders by replacing underwater options with equity awards that have current value and additional vesting requirements.

Industry Context

Equity compensation, including stock options and restricted stock units (RSUs), is a standard practice in the biotechnology and pharmaceutical industries to attract and retain talent, particularly in companies with significant research and development phases. 'Underwater' options, where the exercise price exceeds the current market value, are a common challenge for companies experiencing stock price declines, leading to a loss of incentive value. Option exchange programs are a recognized strategy within the industry to reset incentives and improve employee retention in such scenarios, ensuring that compensation remains a motivating factor for key personnel.

Comparison to Industry Standards

• Option exchange programs are a recognized, albeit sometimes controversial, mechanism employed by companies, particularly in high-growth sectors like biotechnology, when their stock price has significantly underperformed, rendering existing options ineffective as retention or incentive tools.
• The structure of this program, which includes new vesting requirements for the granted RSUs, is standard for such exchanges, aiming to re-establish long-term incentives and align employee interests with future company performance.
• Many biotech peers, such as early-stage biopharmaceutical companies, frequently utilize equity-based compensation to attract and retain specialized talent, and similar option repricing or exchange strategies have been observed across the sector when market conditions impact existing equity awards.

Corporate Governance

Related Party Transactions

• The Option for RSU Exchange Agreements were entered into with a limited number of employees, including Fred Aslan, the company's President and Chief Executive Officer, and Jennifer Bush, the company's Chief Operating Officer, Chief Legal Officer, Corporate Secretary and Compliance Officer. These transactions involve key executives and are part of their compensation structure.

Stakeholder Impact

• Shareholders: Potential for future dilution from the RSU grants (though options were already outstanding). Improved management retention and alignment of interests could be positive for long-term value creation.
• Employees: Enhanced retention and renewed incentive for participating employees whose options were underwater, providing them with equity awards that have current value.
• Management (CEO, COO): Direct benefit through receiving RSUs with current value, replacing options that had lost their incentive, thereby re-establishing a strong link to future company performance.

Next Steps

• Copies of the Option for RSU Exchange Agreements will be filed as exhibits to a subsequent filing with the Securities and Exchange Commission.

Key Dates

Recommendation

The filing indicates a proactive step by management to address a common issue (underwater options) that can demotivate key personnel. While the underlying reason (past stock underperformance) is a concern, the RSU exchange program aims to re-align incentives and improve retention, which is a positive for long-term stability. However, it doesn't present new growth catalysts or immediate financial improvements, hence a 'hold' recommendation, awaiting further operational or financial updates.

Keywords

Artiva Biotherapeutics, ARTV, stock options, restricted stock units, RSUs, equity incentive plan, employee retention, executive compensation, corporate governance, Fred Aslan, Jennifer Bush, biotech, pharmaceutical